2,4-Dichlorobenzyl alcohol does not have a specific molecular target but rather exerts its antimicrobial effect through non-specific disruption of bacterial and fungal cell membranes. The dichloro-substituted benzyl alcohol structure increases lipophilicity, allowing the compound to penetrate microbial cell walls and membranes, leading to increased permeability, leakage of cellular contents, and ultimately cell death. It is effective against a range of Gram-positive and Gram-negative bacteria, as well as some fungi and yeasts.

In vitro, 2,4-Dichlorobenzyl alcohol exhibits antimicrobial activity against a variety of oral and respiratory pathogens. It has been shown to be effective against Streptococcus pyogenes, Staphylococcus aureus, Candida albicans, and other microorganisms associated with throat and mouth infections. Minimum inhibitory concentrations (MICs) typically range from 50-200 ug/mL depending on the organism. The compound demonstrates rapid bactericidal activity, often within 30 seconds to 1 minute of contact. It is often used in combination with amylmetacresol for synergistic effects. In vitro studies have also evaluated its preservative efficacy in multi-dose formulations.

In vivo, 2,4-Dichlorobenzyl alcohol is clinically proven as an active ingredient in throat lozenges and oral antiseptic products. It provides symptomatic relief of sore throat by reducing microbial load in the oral cavity and pharynx. Clinical studies have shown that lozenges containing 1.2 mg of 2,4-dichlorobenzyl alcohol (often combined with 0.6 mg amylmetacresol) significantly reduce sore throat pain and improve symptoms within 2 hours. The compound is well-tolerated with minimal systemic absorption after oral administration as a lozenge or mouthwash.

For antimicrobial susceptibility testing, use the broth microdilution method following CLSI or EUCAST guidelines. Prepare 2-fold serial dilutions of 2,4-dichlorobenzyl alcohol in Mueller-Hinton broth (for bacteria) or RPMI 1640 (for fungi) in 96-well plates, ranging from 1.95 to 1000 ug/mL. Adjust microbial inoculum to 0.5 McFarland standard (approximately 1-5×10⁵ CFU/mL). Inoculate each well, include positive growth control and sterility control. Incubate at 35-37degC for 18-24 h (bacteria) or 48 h (yeasts). Read MIC as the lowest concentration with no visible growth. For time-kill assays, expose microbial suspensions (10⁶ CFU/mL) to 2,4-Dichlorobenzyl alcohol at 1×, 2×, and 4× MIC in broth. At 0, 1, 2, 4, 6, 12, 24 h, plate serial dilutions on agar and count colonies after incubation.

For cytotoxicity studies, culture human oral epithelial cells (e.g., TR146) or gingival fibroblasts in DMEM with 10% FBS at 37degC with 5% CO2. Seed cells in 96-well plates (1×10⁴ cells/well) and incubate overnight. Expose cells to 2,4-Dichlorobenzyl alcohol at concentrations ranging from 10-1000 ug/mL for 5-30 min (mimicking lozenge exposure) or 1-24 h. Assess cell viability by MTT assay or neutral red uptake. Measure LDH release to evaluate membrane damage. For barrier integrity studies, culture Caco-2 or TR146 cells on Transwell inserts until tight junctions form, apply compound to apical side, and measure transepithelial electrical resistance (TEER) and paracellular flux of FITC-dextran. For antimicrobial efficacy on cell monolayers, infect cells with bacteria (e.g., S. pyogenes) at MOI of 10-100 for 1-2 h, then treat with compound, wash, and lyse cells for bacterial enumeration.

For in vivo efficacy in animal models, use male Sprague-Dawley rats (200-250 g) or BALB/c mice (20-25 g) for oral tolerance and local infection models. For oropharyngeal infection model (rats or mice), inoculate the throat mucosa with Streptococcus pyogenes (10⁷-10⁸ CFU) under anesthesia. Administer 2,4-Dichlorobenzyl alcohol (0.5-2 mg/kg) in a lozenge-like format or as an oral spray 3-4 times daily for 3-5 days. Swab the oropharynx before treatment and at 24, 48, 72 h post-treatment for bacterial enumeration. For clinical symptom scoring, observe redness, swelling, and behavior. For systemic toxicity assessment, administer single oral doses (50, 100, 200 mg/kg) by gavage, monitor for 14 days for mortality, body weight, and clinical signs. Collect blood for hematology and serum chemistry at endpoint, and examine major organs by histology.

Absorption, Distribution and Excretion
Dichlorobenzyl alcohol is released almost immediately from the formulation and reaches peak concentration after 3–4 minutes. After 120 minutes, the concentration in saliva is approximately 50% of the administered dose. In preclinical studies, after transdermal administration, 90% of the administered dose of dichlorobenzyl alcohol was eliminated by the kidneys. Following metabolism, dichlorobenzyl alcohol is excreted in the urine. The pharmacokinetic properties of this drug have not been adequately studied. Metabolites/Metabolites Dichlorobenzyl alcohol is metabolized in the liver to hippuric acid. Biological Half-Life The pharmacokinetic properties of this drug have not been adequately studied.

---

2,4-Dichlorobenzyl alcohol has a molecular formula C₇H₆Cl2O and molecular weight 177.03 g/mol. It is a white to off-white crystalline powder with a melting point of 56-60degC. Solubility: slightly soluble in water (approximately 0.7 mg/mL at 25degC), freely soluble in ethanol, chloroform, and propylene glycol. For in vitro assays, prepare stock solutions in ethanol or DMSO at 10-100 mg/mL. For in vivo oral administration, suspend in 0.5% methylcellulose or corn oil. Storage: Keep powder in a tightly sealed container, protected from light, at room temperature or 2-8degC. Solutions should be used fresh or stored at -20degC for short-term. The compound is stable under normal conditions.

The pharmacokinetic properties of protein binding have not been fully studied.

---

2,4-Dichlorobenzyl alcohol is considered safe for topical oral use at concentrations typically found in over-the-counter products (typically 0.5-1.2 mg per lozenge). Acute oral toxicity in rodents: LD₅0 >2000 mg/kg. It is not classified as a hazardous substance at normal use levels. However, for research with high-concentration stock solutions, standard precautions apply: use personal protective equipment (gloves, lab coat), avoid inhalation of dust, and avoid eye contact. Ingestion of large amounts may cause gastrointestinal irritation. The compound is not a skin sensitizer or mutagen based on available data. Consult the safety data sheet before handling. Dispose of waste in accordance with local regulations.

[1]. Amylmetacresol/2,4-dichlorobenzyl alcohol, hexylresorcinol, or carrageenan lozenges as active treatments for sore throat. Int J Gen Med. 2017 Feb 28;10:53-60.

[2]. Spectrum of bactericidal action of amylmetacresol/2,4-dichlorobenzyl alcohol lozenges against oropharyngeal organisms implicated in pharyngitis. Int J Gen Med. 2018 Nov 28;11:451-456.

2,4-Dichlorobenzyl alcohol is a benzyl alcohol compound whose structure involves replacing the hydrogen atoms at positions 2 and 4 with chlorine atoms. It is an antibacterial drug. It belongs to the benzyl alcohol and dichlorobenzene classes of compounds. Dichlorobenzyl alcohol is a mild, broad-spectrum antibacterial agent with antibacterial activity against bacteria and viruses that cause oral and throat infections. Health Canada has listed dichlorobenzyl alcohol as an active ingredient in many commercially available over-the-counter medications and classifies it as an anatomical therapeutic chemical. On the other hand, dichlorobenzyl alcohol is listed as an inactive ingredient in approved drugs by the U.S. Food and Drug Administration (FDA).

---

Drug Indications
Dichlorobenzyl alcohol in combination with [DB13908] can be used over-the-counter to relieve symptoms of acute and postoperative sore throat.

---

Mechanism of Action
The use of dichlorobenzyl alcohol is related to its antibacterial, antiviral, and local anesthetic properties. The local anesthetic effect of dichlorobenzyl alcohol is thought to be due to a reduction in sodium channel blockade.
Mechanism of Action
The application of dichlorobenzyl alcohol is related to its antibacterial, antiviral, and local anesthetic properties. The local anesthetic effect of dichlorobenzyl alcohol is believed to be due to a reduction in sodium channel blockade.
The antibacterial mechanism of dichlorobenzyl alcohol is not fully understood, but it is generally believed to be related to the denaturation of external proteins and the rearrangement of protein tertiary structures.
Pharmacodynamics
In vitro studies have shown that the combined use of dichlorobenzyl alcohol and pentocresol can effectively kill various viruses associated with the common cold, resulting in a reduction in viral load. Clinical trials have shown that dichlorobenzyl alcohol tablets can relieve sore throat and difficulty swallowing within 5 minutes of administration. This effect can last up to 2 hours. The relief effect reaches steady state after 45 minutes.

---

2,4-Dichlorobenzyl alcohol is a well-established active pharmaceutical ingredient in many over-the-counter throat lozenges and mouthwashes (brands include Cepacol, Strepsils, and others). It is commonly combined with amylmetacresol, ascorbic acid, or local anesthetics. The compound is approved in many countries (including the US FDA, EMA, and others) for the symptomatic relief of sore throat, oral infections, and as a preservative in multi-dose pharmaceutical and cosmetic products. Its mechanism of action is membrane disruption, and it has a favorable safety profile with minimal systemic absorption. It is not a prescription drug and is available as a consumer health product. For research use, it serves as an antiseptic reference standard and preservative model compound.

C₇H₆CL₂O

177.03

175.979

1777-82-8

15684

White to off-white solid powder

1.4±0.1 g/cm3

268.4±25.0 °C at 760 mmHg

55-58 °C(lit.)

115.0±17.2 °C

0.0±0.6 mmHg at 25°C

1.583

2.24

1

1

1

10

108

0

DBHODFSFBXJZNY-UHFFFAOYSA-N

InChI=1S/C7H6Cl2O/c8-6-2-1-5(4-10)7(9)3-6/h1-3,10H,4H2

(2,4-dichlorophenyl)methanol

2,4Dichlorobenzyl alcohol; 2,4 Dichlorobenzyl alcohol

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~100 mg/mL (~564.88 mM)

Solubility in Formulation 1: ≥ 2.5 mg/mL (14.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.5 mg/mL (14.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 2.5 mg/mL (14.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

 (Please use freshly prepared in vivo formulations for optimal results.)